{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-140044","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.321071+00:00","generated_at":"2026-05-15T07:53:18.219543+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FibroBiologics closes $3M public offering of common stock and warrants at $1.32/unit","bullets":["Offering of 2,272,728 shares (or pre-funded warrants) plus warrants, combined price $1.32/unit; net proceeds ~$2.5M after fees.","Warrants exercise price $1.32, exercisable only after stockholder approval; if fully cash-exercised, additional $3M proceeds possible.","Pre-funded warrants exercise price $0.00001, no expiration; beneficial ownership cap 9.99%.","Placement agent H.C. Wainwright received 7.0% cash fee, 1.0% management fee, and 159,091 placement agent warrants at $1.65.","Lock-up: insiders 30 days; company restricted from further equity issuance for 30 days and no variable-rate transactions for one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-140044","json":"https://secwatch.observer/filing/0001193125-26-140044.json","markdown":"https://secwatch.observer/filing/0001193125-26-140044.md","text":"https://secwatch.observer/filing/0001193125-26-140044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526140044/0001193125-26-140044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526140044/fblg-20260331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:53:18.219543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"edb4c4f507377c1ef8d7746590173d809b80ae30","claim":"FibroBiologics, Inc. entered into Purchase Agreement with certain investors (effective 2026-03-31).","evidence_excerpt":"certain of the investors purchased their Shares and Pre-Funded Warrants, together with the accompanying Warrants, pursuant to a securities purchase agreement, dated March 31, 2026, by and among the Company and such investors (the “Purchase Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1958777/000119312526140044/0001193125-26-140044-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Effective","value":"2026-03-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}